For the year ending 2025-12-31, SUPN has $1,452,648K in assets. $390,934K in debts. $128,448K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 128,448 | |||
| Marketable securities | 180,222 | |||
| Accounts receivable, net | 187,802 | |||
| Inventories, net | 82,385 | |||
| Prepaid expenses and other current assets | 65,325 | |||
| Total current assets | 644,182 | |||
| Restricted cash | 1,450 | |||
| Property and equipment, net | 10,531 | |||
| Intangible assets, net | 569,456 | |||
| Goodwill | 124,882 | |||
| Deferred income tax assets, net | 38,351 | |||
| Other assets | 63,796 | |||
| Total assets | 1,452,648 | |||
| Accounts payable and accrued liabilities | 107,800 | |||
| Accrued product returns and rebates | 161,097 | |||
| Contingent consideration, current portion | 31,052 | |||
| Other current liabilities | 38,222 | |||
| Total current liabilities | 338,171 | |||
| Contingent consideration, long-term | 206 | |||
| Operating lease liabilities, long-term | 30,365 | |||
| Deferred income tax liabilities, net | 0 | |||
| Other liabilities | 22,192 | |||
| Total liabilities | 390,934 | |||
| Common stock, 0.001 par value 130,000,000 shares authorized 57,457,462 and 55,743,095 shares issued and outstanding as of december31, 2025 and december31, 2024, respectively | 57 | |||
| Additional paid-in capital | 543,825 | |||
| Accumulated other comprehensive loss, net of tax | -44 | |||
| Retained earnings | 517,876 | |||
| Total stockholders' equity | 1,061,714 | |||
| Total liabilities and stockholders' equity | 1,452,648 | |||
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)